糖尿病治療薬の世界市場規模：薬剤別、糖尿病タイプ別、流通チャネル別、地域範囲別および予測

糖尿病治療薬の市場規模と予測

糖尿病治療薬の市場規模は、2025年に667億2,000万米ドルと評価され、2026～2032年にかけてCAGR 6.00%で成長し、2032年には1,019億2,000万米ドルに達すると予測されます。

糖尿病医薬品は、糖尿病患者の血糖値調節を助けるために使用される医薬品です。糖尿病は、体内でインスリンが十分に分泌されない（1型）か、インスリンに抵抗性を示す（2型）慢性疾患です。これらの薬は、糖尿病タイプや患者の要求に応じて様々な作用を示します。

糖尿病治療薬は、1型糖尿病と2型糖尿病の両方を管理し、正常な血糖値を維持し、合併症のリスクを下げるために患者を支援するために重要です。糖尿病治療薬は、インスリン、スルホニル尿素、メトホルミン、GLP-1受容体作動薬やSGLT2阻害剤などの新しい治療など、いくつかのカテゴリーに分類されます。

糖尿病治療薬の将来は、継続的な研究と技術の飛躍的進歩により、有望と考えられます。世界の糖尿病有病率の上昇に加え、オーダーメイド治療が重視されるようになったことで、特定の患者のニーズに対応した治療の開発が進むと予測されます。新たな薬剤製剤や併用療法は、悪影響を最小限に抑えながら有効性を向上させるために研究されています。

糖尿病治療薬の世界市場力学

世界の糖尿病治療薬市場を形成している主要市場力学は以下の通りです。

主要市場促進要因

糖尿病の有病率の上昇：糖尿病の有病率の上昇：糖尿病はより一般的になりつつあり、特に2型糖尿病は糖尿病治療薬産業の主要な牽引役となっています。国際糖尿病連合によると、糖尿病を患う成人の数は2045年までに7億人に達すると予測されており、効果的な糖尿病治療薬の選択肢に対する需要が高まっています。

医薬品開発の進歩：医薬品研究開発の絶え間ない進歩は、糖尿病治療薬産業に大きな影響を与えています。SGLT2阻害剤、GLP-1受容体作動薬、DPP-4阻害剤などの革新的な治療の開発により、糖尿病治療薬の選択肢が増加しています。これらの新しい薬剤クラスは、優れた有効性と安全性プロファイルに加え、体重減少や心血管保護などのその他の特典を記載しています。

認知度の向上とスクリーニングプログラム糖尿病とその影響に関する知識の増加により、より積極的なスクリーニングと早期診断が行われるようになっています。政府プログラムやヘルスケア機関は、糖尿病コントロールの必要性や早期介入の利点についての認識を高めています。

主要課題

高い開発コスト：糖尿病治療薬の研究開発（R&D）には特に多額の費用がかかります。その理由は、糖尿病という疾病の複雑さと、安全性と有効性を確認するために必要な広範な検査にあります。新規糖尿病治療薬の開発には、厳しい前臨床研究、臨床検査、規制当局の認可が必要であり、これには長い年月と多額の資金が必要となります。

産業の競合と価格圧力：糖尿病治療薬産業は、複数の既存企業やさまざまなジェネリック医薬品が存在するため、激しい競争が繰り広げられています。このような厳しい競争は、ブランド薬メーカーとジェネリック医薬品メーカーの利益率に影響を及ぼす可能性のある大きな価格圧力となっています。

アドヒアランスと患者のコンプライアンス：患者が糖尿病治療薬を配合通りに確実に服用することは、依然として大きな懸念事項です。複雑な投与レジメン、副作用、不十分な患者教育などがすべてコンプライアンス低下の原因となります。コンプライアンス違反は、治療成績の低下、医療費の増加、結果リスクの増大を招く可能性があります。

主要動向

GLP-1受容体作動薬への注目の高まり：糖尿病治療薬産業はグルカゴン様ペプチド-1（GLP-1）受容体作動薬に大きくシフトしています。これらの薬剤は血糖値のコントロールを助けるだけでなく、体重減少も助けるため、肥満や過体重の多い2型糖尿病患者には特に魅力的です。これらの薬剤の2つの利点により、配合と需要が増加しています。

バイオシミラーの出現：人気の糖尿病治療薬の特許が切れるにつれて、バイオシミラーが目立つようになってきました。これらの生物学的に同等な医薬品は、先発医薬品よりも安価であるため、患者の利便性が向上しています。バイオシミラーは、糖尿病治療薬産業における競争を促進し、価格を引き下げて、より多くの患者が重要な治療を入手できるようにすると予測されています。

技術統合とデジタルヘルスソリューション：糖尿病管理における技術の活用は、治療技術を変革しつつあります。モバイルアプリ、ウェアラブル・ガジェット、持続グルコース・モニタリングシステムは、糖尿病治療薬と併用されることが増えており、患者の治療成績を向上させています。これらの技術はリアルタイムのデータと洞察をもたらし、患者やヘルスケアプロバイダは、糖尿病管理の改善につながる投薬の変更やライフスタイルの変更について、より教育的な決定を下すことができます。

目次

第1章 世界の糖尿病治療薬市場の導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 糖尿病治療薬の世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 糖尿病治療薬の世界市場：薬剤別

• 概要
• 注射薬
• 経口薬
• インスリン製剤
• その他

第6章 糖尿病治療薬の世界市場：糖尿病タイプ別

• 概要
• 1型
• 2型

第7章 糖尿病治療薬の世界市場：流通チャネル別

• 概要
• 病院薬局
• レンタル薬局
• オンライン薬局
• その他

第8章 糖尿病治療薬の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋
• その他
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界の糖尿病治療薬市場の競合情勢

• 概要
• 各社の市場ランキング
• 主要開発戦略

第10章 企業プロファイル

• Novo Nordisk
• AstraZeneca
• Biocon
• Sanofi
• Eli Lilly
• Johnson & Johnson
• Bristol Myers Squibb
• BoehringerIngelheim
• Pfizer

第11章 付録

• 関連調査

Diabetes Drugs Market Size and Forecast

Diabetes Drugs Market size was valued at USD 66.72 Billion in 2025 and is projected to reach USD 101.92 Billion by 2032, growing at a CAGR of 6.00% from 2026 to 2032.

Diabetes pharmaceuticals are medications used to help people with diabetes regulate their blood sugar levels. Diabetes is a chronic disorder in which the body either does not produce enough insulin (Type 1) or becomes resistant to insulin (Type 2). These medications act in a variety of ways depending on the kind of diabetes and the patient's requirements.

They are critical for managing both Type 1 and Type 2 diabetes assisting patients in maintaining normal blood glucose levels and lowering the risk of complications. Diabetes drugs are classified into several categories including insulin, sulfonylureas, metformin, and newer treatments such as GLP-1 receptor agonists and SGLT2 inhibitors.

The future of diabetic medications seems promising, thanks to continued research and technological breakthroughs. The rising global prevalence of diabetes combined with a growing emphasis on customized treatment is projected to result in the development of increasingly focused medications that address specific patient needs. Novel medication formulations and combination therapies are being investigated to improve efficacy while minimizing negative effects.

Global Diabetes Drugs Market Dynamics

The key market dynamics that are shaping the global diabetes drugs market include:

Key Market Drivers:

Rising Prevalence of Diabetes: Diabetes is becoming more common, particularly Type 2 diabetes which is a major driver of the diabetic medications industry. According to the International Diabetes Federation, the number of adults living with diabetes is predicted to reach 700 million by 2045 increasing the demand for effective diabetes care options.

Advancements in Medicine Development: Continuous advances in pharmaceutical research and development are having a substantial impact on the diabetic medicine industry. The development of innovative medicines such as SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors has increased the number of diabetes treatment options. These newer medication classes provide superior efficacy and safety profiles as well as additional benefits like weight loss and cardiovascular protection.

Improving Awareness and Screening Programs: Increased knowledge of diabetes and its implications is resulting in greater proactive screening and early diagnosis. Government programs and healthcare organizations are raising awareness about the necessity of diabetes control and the advantages of early intervention.

Key Challenges:

High Development Costs: Diabetes medications incur particularly high research and development (R&D) expenses due to the disease's complexity and the extensive testing required for safety and efficacy. Creating novel diabetic drugs takes rigorous preclinical research, clinical trials, and regulatory clearances which can take years and need significant financial expenditure.

Industry Competition and Pricing Pressure: The diabetic medicine industry is fiercely competitive with multiple established businesses and a variety of generic alternatives. This severe rivalry causes significant pricing pressure which can have an influence on both branded and generic medicine producers' profit margins.

Adherence and Patient Compliance: Ensuring that patients take their diabetes medications as prescribed remains a substantial concern. Complex dose regimens, adverse effects, and inadequate patient education can all contribute to low compliance rates. Noncompliance can lead to inferior treatment outcomes increased healthcare expenses, and an increased risk of consequences.

Key Trends:

Increased Focus on GLP-1 Receptor Agonists: The diabetes treatment industry is shifting significantly towards glucagon-like peptide-1 (GLP-1) receptor agonists. These drugs not only assist control of blood sugar levels but also aid in weight loss making them especially appealing to type 2 diabetics who are frequently overweight or obese. The dual benefits of these medications have resulted in increased prescriptions and demand.

Emergence of Biosimilars: As patents for numerous popular diabetic drugs expire, biosimilars are becoming a prominent trend. These biologically comparable pharmaceuticals are less expensive than branded medications, giving patients better access. Biosimilars are projected to boost competition in the diabetic medicine industry lowering prices and allowing more patients to obtain critical therapies.

Technological Integration and Digital Health Solutions: The use of technology in diabetes management is transforming treatment techniques. Mobile apps, wearable gadgets, and continuous glucose monitoring systems are increasingly being used with diabetes medications to improve patient results. These technologies give real-time data and insights allowing patients and healthcare providers to make more educated decisions about medication modifications and lifestyle changes resulting in improved diabetes management.

Global Diabetes Drugs Market Regional Analysis

Here is a more detailed regional analysis of the global diabetes drugs market:

North America:

The North American diabetes medicine industry is primarily driven by the rising prevalence of diabetes and obesity as well as an aging population and sedentary habits. This supremacy stems partly from the region's advanced healthcare infrastructure, high healthcare spending, and the presence of big pharmaceutical companies that invest extensively in diabetes research and treatment development. According to the Centers for Disease Control and Prevention (CDC), an estimated 37.3 million Americans (11.3% of the population) will have diabetes by 2023, with another 96 million individuals suffering from prediabetes.

The market is also being driven by technical developments in drug delivery systems and the growing acceptance of innovative diabetes care regimens. The United States Food and Drug Administration (FDA) authorized five new diabetic medications in 2023, demonstrating the field's continued innovation. Furthermore, the National Institutes of Health (NIH) has committed $1.2 billion for diabetes research in fiscal year 2023, demonstrating the government's commitment to addressing this health epidemic.

Asia Pacific:

The Asia Pacific region is seeing the highest growth in the diabetes medications market owing to a rapidly growing diabetic population and improved healthcare infrastructure. This fast growth is fueled by changing lifestyles, urbanization, and rising obesity rates, particularly in China and India. According to the International Diabetes Federation (IDF), the number of diabetic people in the Western Pacific region, which includes much of Asia, is anticipated to climb by 46%, from 163 million in 2021 to 238 million by 2045.

The Asian Development Bank (ADB) expects Asia's GDP to grow by 4.8% in 2024, with many countries investing considerably in healthcare facilities. According to the World Bank, China's healthcare expenditure will account for 6.5% of its GDP in 2020, up from 4.5% in 2000. India's National Health Policy seeks to raise public health spending to 2.5% of GDP by 2025. The increase in disposable income is also contributing to higher healthcare costs. According to the World Bank, GDP per capita in East Asia and the Pacific has improved from $1,957 in 2000 to $11,487 in 2021, allowing for better access to diabetes drugs.

Global Diabetes Drugs Market: Segmentation Analysis

The Global Diabetes Drugs Market is segmented based on Drug, Diabetes Type, Distribution Channel, and Geography.

Diabetes Drugs Market, By Drug

• Injectable Drugs
• Oral Drugs
• Insulins
• Others

Based on the Drug, the Global Diabetes Drugs Market is bifurcated into Injectable Drugs, Oral Drugs, Insulins, and Others. The insulin segment dominates the global diabetes drugs market due to its essential role in managing blood sugar levels for individuals with Type 1 and advanced Type 2 diabetes. Insulin therapy is critical for patients who cannot produce adequate insulin naturally making it a cornerstone of diabetes management. The increasing prevalence of diabetes worldwide, particularly in the Asia Pacific and North America drives the demand for insulin products. Additionally, advancements in insulin formulations and delivery methods such as pen devices and continuous glucose monitors enhance patient adherence and treatment outcomes.

Diabetes Drugs Market, By Diabetes Type

• Type 1
• Type 2

Based on the Diabetes Type, the Global Diabetes Drugs Market is bifurcated into Type 1, and Type 2. The Type 2 diabetes segment dominates the global diabetes drugs market, primarily due to the higher prevalence of this condition compared to Type 1 diabetes. Type 2 diabetes accounts for approximately 90-95% of all diabetes cases, largely driven by rising obesity rates, sedentary lifestyles, and an aging population. The increased focus on lifestyle management including weight loss and dietary changes further propels demand for various therapeutic options. Additionally, advancements in treatment options such as oral medications and injectable therapies, specifically targeting Type 2 diabetes enhance the segment's growth.

Diabetes Drugs Market, By Distribution Channel

• Hospital Pharmacies
• Rental Pharmacies
• Online Pharmacies
• Others

Based on the Distribution Channel, the Global Diabetes Drugs Market is bifurcated into Hospital Pharmacies, Rental Pharmacies, Online Pharmacies, and Others. The dominant distribution channel in the global diabetes drugs market is hospital pharmacies. This is primarily due to their critical role in managing diabetes care where healthcare professionals closely monitor and provide medications to patients with complex needs. Hospital pharmacies often offer a wide range of diabetes medications including insulin and oral hypoglycemic agents ensuring that patients receive appropriate treatment during their hospital stay. Additionally, hospital pharmacies are integral in providing patient education and personalized medication management which is vital for diabetes control.

Diabetes Drugs Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Global Diabetes Drugs Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. The North American region dominates the global diabetes drugs market primarily due to its advanced healthcare infrastructure, high prevalence of diabetes, and significant investments in research and development. The United States accounts for a substantial share of the market driven by a growing aging population and increasing rates of obesity which contribute to the rising incidence of diabetes.

Key Players

The "Global Diabetes Drugs Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Novo Nordisk, Biocon, AstraZeneca, Sanofi, BoehringerIngelheim, Eli Lilly, Johnson & Johnson, Pfizer, and Bristol Myers Squibb.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Diabetes Drugs Market Key Developments

• In January 2024, Glenmark Pharmaceuticals Ltd. released Lirafit, a biosimilar to the anti-diabetic medication Liraglutide, in India. The daily cost of this medicine is around USD 1.21 for a normal dose of 1.2 mg.
• In June 2023, Pfizer, Inc. said that it would continue clinical development of its oral GLP-1-RA candidate for the treatment of adults with type 2 diabetes and obesity.
• March 2023 - The Central Drugs Standard Control Organization (CDSCO) in India granted Sanofi (India) a marketing license for their diabetes medicine Soliqua.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL DIABETES DRUGS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL DIABETES DRUGS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL DIABETES DRUGS MARKET, BY DRUG

• 5.1 Overview
• 5.2 Injectable Drugs
• 5.3 Oral Drugs
• 5.4 Insulins
• 5.5 Others

6 GLOBAL DIABETES DRUGS MARKET, BY DIABETES TYPE

• 6.1 Overview
• 6.2 Type1
• 6.3 Type 2

7 GLOBAL DIABETES DRUGS MARKET, BY DISTRIBUTION CHANNEL

• 7.1 Overview
• 7.2 Hospital Pharmacies
• 7.3 Rental Pharmacies
• 7.4 Online Pharmacies
• 7.5 Others

8 GLOBAL DIABETES DRUGS MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East And Africa

9 GLOBAL DIABETES DRUGS MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Novo Nordisk
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 AstraZeneca
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Biocon
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Sanofi
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Eli Lilly
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Johnson & Johnson
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Bristol Myers Squibb
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 BoehringerIngelheim
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Pfizer
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments

11 Appendix

• 11.1 Related Research